The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.
From evolving healthcare laws to social engagement, litigation crises to media relations, McKesson's PR chief is hands-on in efforts to enhance the brand's image.
Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010
Test your knowledge in this week's edition of the MM&M Weekly News Quiz.
Lawsuit alleges CVS overbilled insurance companies for generic drugs; a Merck vaccine is shown to be effective in treating Ebola; the FDA approves Bayer's rosacea treatment
The New York-based agency took a majority stake in the full-service healthcare agency.
The "Surprise, it's insulin" campaign follows criticism of the lower-than-expected sales of the inhaled insulin since its launch in February.
Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US
More patients are seeking treatments with even fewer side effects and shorter durations.
Turing Pharmaceuticals hired Craig Rothenberg, who spent 20 years with Johnson & Johnson, to lead the recently founded drugmaker's communications operations.